查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞/基因治疗临床试验市场规模、份额、趋势分析报告：阶段（I、II、III、IV）、适应症（肿瘤、CNS）、地区（亚太地区、北美）、分部预测，2022-2030 年版
市场调查报告书
商品编码
1097117

细胞/基因治疗临床试验市场规模、份额、趋势分析报告：阶段（I、II、III、IV）、适应症（肿瘤、CNS）、地区（亚太地区、北美）、分部预测，2022-2030 年版

Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Indication (Oncology, CNS), By Region (Asia Pacific, North America), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 275 Pages | 商品交期: 2-10个工作天内

价格

细胞/基因治疗临床试验市场的增长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年，全球细胞和基因治疗临床试验市场规模将达到 245 亿美元，预测期内復合年增长率为 14.6%。预计记录。

细胞和基因疗法 (CGT) 代表了治疗创新的下一个重大举措，并导致了全球有前景的疗法的发展。儘管一些早期治疗方法已获准在美国销售，但世界各地已开发出许多有前景的治疗方法。在大流行期间，大部分临床研究都集中在 COVID-19 上。然而，随着 COVID-19 病例数量的减少，市场参与者现在正将注意力转移到 CGT 的开发上。

例如，2022 年 2 月，生命科学公司 Citiva 与 NecstGen 合作开发基因治疗药物。这种合作研究可能会在大流行之后推动市场增长。随着 CGT 管道的增加，市场在过去几年中显着增长。 Global Data 报告称，2021 年 3 月有超过 2,400 种 CGT 药物在研，而 2020 年有超过 551 种 CGT 药物处于临床阶段。从初创企业到大型生物製药公司的大规模收购，不同类型的公司也在不断投资。 2019年完成19宗併购交易，金额超过1560亿美元。

其中最大的一笔交易是百时美施贵宝以 740 亿美元收购 Celgene 及其用于治疗癌症的细胞治疗资产管道。随着 CGT 在治疗危及生命的疾病方面越来越受欢迎，这些交易可能会促进市场增长。 CGT 研究经费在大流行后时期有所改善。例如，2022 年 1 月，约克大学的研究人员获得了 310 万美元的赠款，用于支持干细胞基因疗法研究以治疗镰状细胞病。 2022 年 3 月，印第安纳大学的研究人员获得了 1200 万美元的资金，用于开发治疗血友病的安全基因疗法。此类投资可能会对市场增长产生积极影响。

细胞/基因治疗临床试验市场报告亮点。

  • 由于目前在第二阶段开发的大量治疗方法，第二阶段部分在 2021 年占最大份额。
  • 由于大量 CGT 试验集中在癌症治疗上，2021 年癌症适应症细分市场份额最大。
  • 2021 年，北美主导了全球市场。这主要得益于美国众多的临床试验活动和政府的大力支持。
  • 由于专注于 CGT 的生物技术公司的增加，预计亚太地区将在预测期内录得最快的复合年增长率

目录

第 1 章调查方法及范围

  • 市场细分和范围
    • 阶段
    • 显示
    • 区域范围
    • 估计/预测时间线
  • 调查方法
  • 资讯采购
    • 购买的数据库
    • Gvr 的内部数据库
    • 二次材料
    • 初步调查
    • 初步调查详情
  • 资讯或数据分析
    • 数据分析模型
  • 市场製定与验证
  • 型号详情
    • 产品流分析
  • 二次材料清单
  • 主要来源列表
  • 缩写列表
  • 目的
    • 目的-1
    • 目的-2
    • 目的-3
    • 目的-4

第 2 章执行摘要

  • 市场展望
  • 竞争考虑

第 3 章细胞和基因治疗临床试验市场：变量、趋势和范围

  • 市场体系展望
    • 母公司市场展望
    • 辅助市场展望
  • 渗透率和增长前景映射
  • COVID-19 大流行对临床试验活动的影响
    • 暂停临床试验
      • 解决与 COVID-19 相关的製造和供应问题
      • 其他问题
  • 市场动态
    • 市场促进因素分析
      • 对细胞和基因治疗的兴趣日益浓厚
      • 在临床研究中采用新技术
      • 加大投入和研发经费
    • 市场抑制分析
      • 招聘障碍
    • 行业挑战
      • 临床试验成本增加
    • 重大交易和战略联盟分析
      • 推出产品/服务
      • 併购
      • 协作与伙伴关係
      • 调查范围扩大
      • 服务扩展
    • 监管框架
    • 美国
    • 欧洲
    • 中国
      • 销售未经批准的细胞疗法的监管挑战和风险
    • 日本
  • 细胞和基因治疗临床试验市场分析工具
    • 波特五力分析
    • PESTEL 分析

第 4 章细胞和基因治疗临床试验市场：阶段细分分析

  • 细胞和基因治疗临床试验：市场份额分析，2021 年和 2030 年
  • 第一阶段
    • 一期市场，2018-2030
  • 第二阶段
    • 二期市场，2018-2030
  • 第三阶段
    • 三期市场，2018-2030
  • 第四阶段
    • 四期市场，2018-2030

第 5 章细胞和基因治疗临床试验市场：适应症细分分析

  • 细胞和基因治疗临床试验：市场份额分析，2021 年和 2030 年
  • 肿瘤学
    • 2018-2030 年肿瘤市场
  • 心臟病学
    • 2018-2030 年心脏病市场
  • 中枢神经系统
    • CNS 市场，2018-2030
  • 肌肉骨骼
    • 2018-2030 年肌肉骨骼市场
  • 传染病
    • 2018-2030 年传染病市场
  • 皮肤科
    • 2018-2030 年皮肤科市场
  • 内分泌、新陈代谢、遗传
    • 内分泌、代谢、基因市场，2018-2030
  • 免疫学和炎症
    • 2018-2030 年免疫学和炎症市场
  • 眼科
    • 2018-2030年眼科市场
  • 血液学
    • 2018-2030年血液学市场
  • 胃肠道
    • 2018-2030年胃肠市场
  • 其他
    • 2018-2030 年其他市场

第 6 章细胞和基因治疗临床试验市场：区域分析

  • 细胞和基因治疗临床试验：区域市场份额
  • 细胞和基因治疗临床试验：市场份额分析，2021 年和 2028 年
  • 北美
    • 2018-2030 年北美细胞和基因治疗临床试验市场
    • 美国
      • 2018-2030年美国细胞和基因治疗临床试验市场
    • 加拿大
      • 2018-2030 年加拿大细胞和基因治疗临床试验市场
  • 欧洲
    • 2018-2030 年欧洲细胞和基因治疗临床试验市场
    • 英国
      • 2018-2030 年英国细胞和基因治疗临床试验市场
    • 德国
      • 2018-2030 年德国细胞和基因治疗临床试验市场
    • 法国
      • 2018-2030 年法国细胞和基因治疗临床试验市场
    • 义大利
      • 2018-2030 年意大利细胞和基因治疗临床试验市场
    • 西班牙
      • 2018-2030 年西班牙细胞和基因治疗临床试验市场
  • 亚太地区
    • 2018-2030 年亚太地区细胞和基因治疗临床试验市场
    • 印度
      • 2018-2030 年印度细胞和基因治疗临床试验市场
    • 日本
      • 2018-2030 年日本细胞和基因治疗临床试验市场
    • 中国
      • 2018-2030年中国细胞与基因治疗临床试验市场
    • 澳大利亚
      • 2018-2030 年澳大利亚细胞和基因治疗临床试验市场
    • 韩国
      • 2018-2030 年韩国细胞和基因治疗临床试验市场
  • 拉丁美洲
    • 2018-2030 年拉丁美洲细胞和基因治疗临床试验市场
    • 巴西
      • 2018-2030 年巴西细胞和基因治疗临床试验市场
    • 墨西哥
      • 2018-2030 年墨西哥细胞和基因治疗临床试验市场
    • 阿根廷
      • 2018-2030 年阿根廷细胞和基因治疗临床试验市场
    • 哥伦比亚
      • 2018-2030 年哥伦比亚细胞和基因治疗临床试验市场
  • 多边环境协定
    • 2018-2030年MEA细胞和基因治疗临床试验市场
    • 南非
      • 2018-2030 年南非细胞和基因治疗临床试验市场
    • 沙特阿拉伯
      • 2018-2030 年沙特阿拉伯细胞和基因治疗临床试验市场
    • 阿拉伯联合酋长国
      • 2018-2030 年阿拉伯联合酋长国细胞和基因治疗临床试验市场

第 7 章公司简介

  • 公司简介
    • ICON Plc
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • IQVIA
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • SYNEOS HEALTH
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • MEDPACE HOLDINGS, INC.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • PPD, INC.
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • PAREXEL INTERNATIONAL Corporation
      • 公司简介
      • 财务表现
      • 产品基准
      • 战略举措
    • NOVOTECH
      • 公司简介
      • 产品基准
      • 战略举措
    • VERISTAT, LLC
      • 公司简介
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-409-7

Cell And Gene Therapy Clinical Trials Market Growth & Trends:

The global cell and gene therapy clinical trials market size is expected to reach USD 24.5 billion by 2030, registering a CAGR of 14.6% during the forecast period, according to a new report by Grand View Research, Inc. Cell and gene therapy (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world. During the pandemic, the majority of clinical studies were focused on COVID-19. However, owing to the decline in COVID-19 cases, the market players are now shifting their focus to the development of CGTs.

For instance, in February 2022, the life sciences company, Cytiva, collaborated with NecstGen to develop gene therapies. Such collaborations are likely to promote market growth post-pandemic. The market has witnessed significant growth over the past few years, with a rise in the CGT pipeline. As reported by Global Data, in March 2021, over 2,400 CGT drugs were in the pipeline, whereas in 2020 there were over 551 CGT drugs in the clinical phase. In addition, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed.

The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets for oncology treatment by Bristol-Myers Squibb for USD 74 billion. Such deals are likely to improve the market growth as CGT is gaining popularity in the treatment of life-threatening diseases. Research funding in CGT has improved in the post-pandemic period. For instance, in January 2022, researchers at the University of York received a grant of USD 3.1 million to support stem cell gene therapy research to treat sickle cell disease. In March 2022, researchers at the Indiana University School received funding of USD 12 million to develop safe gene therapy for treating hemophilia. Such investments are likely to have a positive impact on market growth.

Cell And Gene Therapy Clinical Trials Market Report Highlights:

  • The phase II segment accounted for the largest share in 2021 owing to a large number of therapies currently in development in phase II
  • The oncology indication segment accounted for the largest share in 2021 as a high number of CGT trials are focused on the treatment of cancer
  • North America dominated the global market in 2021. This is largely attributed to a large number of clinical trial activities in the U.S. and favorable government support
  • Asia Pacific is expected to register the fastest CAGR over the forecast period owing to the increasing number of biotechnology companies focusing on CGTs

Table Of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Phase
    • 1.1.2 Indication
    • 1.1.3 Regional Scope
    • 1.1.4 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1
    • 1.10.2 Objective - 2
    • 1.10.3 Objective - 3
    • 1.10.4 Objective - 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Competitive Insights

Chapter 3 Cell And Gene Therapy Clinical Trials Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 COVID-19 Pandemic Impact On Clinical Trial Activity
    • 3.3.1 Disrupted Clinical Trials
      • 3.3.1.1 Troubleshooting The Manufacturing & Supply Challenges Associated To COVID-19
      • 3.3.1.2 Other Challenges
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Growing Interest In Cell And Gene Therapy
      • 3.4.1.2 Adoption Of New Technology In Clinical Research
      • 3.4.1.3 Increasing Investments And R&D Funding
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Recruitment Obstacles
    • 3.4.3 Industry Challenges
      • 3.4.3.1 Rising Cost Of Clinical Trial
    • 3.4.4 Major Deals & Strategic Alliances Analysis
      • 3.4.4.1 Product/Service Launch
      • 3.4.4.2 Merger & Acquisition
      • 3.4.4.3 Collaboration & Partnership
      • 3.4.4.4 Research Expansion
      • 3.4.4.5 Service Expansion
    • 3.4.5 Regulatory Framework
    • 3.4.6 U.S.
    • 3.4.7 Europe
    • 3.4.8 China
      • 3.4.8.1 Regulatory Challenges & Risk Of Selling Unapproved Cell Therapies
    • 3.4.9 Japan
  • 3.5 Cell And Gene Therapy Clinical Trials Market Analysis Tools
    • 3.5.1 Porter's Five Forces Analysis
    • 3.5.2 PESTEL Analysis

Chapter 4 Cell And Gene Therapy Clinical Trials Market: Phase Segment Analysis

  • 4.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
  • 4.2 Phase I
    • 4.2.1 Phase I Market, 2018 - 2030 (USD Million)
  • 4.3 Phase II
    • 4.3.1 Phase II Market, 2018 - 2030 (USD Million)
  • 4.4 Phase III
    • 4.4.1 Phase III Market, 2018 - 2030 (USD Million)
  • 4.5 Phase IV
    • 4.5.1 Phase IV Market, 2018 - 2030 (USD Million)

Chapter 5 Cell And Gene Therapy Clinical Trials Market: Indication Segment Analysis

  • 5.1 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2030
  • 5.2 Oncology
    • 5.2.1 Oncology Market, 2018 - 2030 (USD Million)
  • 5.3 Cardiology
    • 5.3.1 Cardiology Market, 2018 - 2030 (Usd Million)
  • 5.4 CNS
    • 5.4.1 CNS Market, 2018 - 2030 (USD Million)
  • 5.5 Musculoskeletal
    • 5.5.1 Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 5.6 Infectious Diseases
    • 5.6.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.7 Dermatology
    • 5.7.1 Dermatology Market, 2018 - 2030 (USD Million)
  • 5.8 Endocrine, Metabolic, Genetic
    • 5.8.1 Endocrine, Metabolic, Genetic Market, 2018 - 2030 (USD Million)
  • 5.9 Immunology & Inflammation
    • 5.9.1 Immunology & Inflammation Market, 2018 - 2030 (USD Million)
  • 5.10 Ophthalmology
    • 5.10.1 Ophthalmology Market, 2018 - 2030 (USD Million)
  • 5.11 Hematology
    • 5.11.1 Haematology Market, 2018 - 2030 (USD Million)
  • 5.12 Gastrointestinal
    • 5.12.1 Gastrointestinal Market, 2018 - 2030 (USD Million)
  • 5.13 Others
    • 5.13.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Cell And Gene Therapy Clinical Trials Market: Regional Analysis

  • 6.1 Cell And Gene Therapy Clinical Trials: Regional Market Share
  • 6.2 Cell And Gene Therapy Clinical Trials: Market Share Analysis, 2021 & 2028
  • 6.3 North America
    • 6.3.1 North America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.3.2 U.S.
      • 6.3.2.1 U.S. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.3.3 Canada
      • 6.3.3.1 Canada Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • 6.4 Europe
    • 6.4.1 Europe Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.4.2 U.K.
      • 6.4.2.1 U.K. Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.4.3 Germany
      • 6.4.3.1 Germany Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.4.4 France
      • 6.4.4.1 France Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.4.5 Italy
      • 6.4.5.1 Italy Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.4.6 Spain
      • 6.4.6.1 Spain Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • 6.5 Asia Pacific
    • 6.5.1 Asia Pacific Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.5.2 India
      • 6.5.2.1 India Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.5.3 Japan
      • 6.5.3.1 Japan Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.5.4 China
      • 6.5.4.1 China Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.5.5 Australia
      • 6.5.5.1 Australia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.5.6 South Korea
      • 6.5.6.1 South Korea Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • 6.6 Latin America
    • 6.6.1 Latin America Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.6.2 Brazil
      • 6.6.2.1 Brazil Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.6.3 Mexico
      • 6.6.3.1 Mexico Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.6.4 Argentina
      • 6.6.4.1 Argentina Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.6.5 Colombia
      • 6.6.5.1 Colombia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • 6.7 MEA
    • 6.7.1 MEA Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.7.2 South Africa
      • 6.7.2.1 South Africa Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.7.3 Saudi Arabia
      • 6.7.3.1 Saudi Arabia Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
    • 6.7.4 UAE
      • 6.7.4.1 UAE Cell And Gene Therapy Clinical Trials Market, 2018 - 2030 (USD Million)

Chapter 7 Company Profiles

  • 7.1 Company Profiles
    • 7.1.1 ICON Plc
      • 7.1.1.1 Company Overview
      • 7.1.1.2 Financial Performance
      • 7.1.1.3 Product Benchmarking
      • 7.1.1.4 Strategic Initiatives
    • 7.1.2 IQVIA
      • 7.1.2.1 Company Overview
      • 7.1.2.2 Financial Performance
      • 7.1.2.3 Product Benchmarking
      • 7.1.2.4 Strategic Initiatives
    • 7.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 7.1.3.1 Company Overview
      • 7.1.3.2 Financial Performance
      • 7.1.3.3 Product Benchmarking
      • 7.1.3.4 Strategic Initiatives
    • 7.1.4 SYNEOS HEALTH
      • 7.1.4.1 Company Overview
      • 7.1.4.2 Financial Performance
      • 7.1.4.3 Product Benchmarking
      • 7.1.4.4 Strategic Initiatives
    • 7.1.5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
      • 7.1.5.1 Company Overview
      • 7.1.5.2 Financial Performance
      • 7.1.5.3 Product Benchmarking
      • 7.1.5.4 Strategic Initiatives
    • 7.1.6 MEDPACE HOLDINGS, INC.
      • 7.1.6.1 Company Overview
      • 7.1.6.2 Financial Performance
      • 7.1.6.3 Product Benchmarking
      • 7.1.6.4 Strategic Initiatives
    • 7.1.7 PPD, INC.
      • 7.1.7.1 Company Overview
      • 7.1.7.2 Financial Performance
      • 7.1.7.3 Product Benchmarking
      • 7.1.7.4 Strategic Initiatives
    • 7.1.8 PAREXEL INTERNATIONAL Corporation
      • 7.1.8.1 Company Overview
      • 7.1.8.2 Financial Performance
      • 7.1.8.3 Product Benchmarking
      • 7.1.8.4 Strategic Initiatives
    • 7.1.9 NOVOTECH
      • 7.1.9.1 Company Overview
      • 7.1.9.2 Product Benchmarking
      • 7.1.9.3 Strategic Initiatives
    • 7.1.10 VERISTAT, LLC
      • 7.1.10.1 Company Overview
      • 7.1.10.2 Product Benchmarking
      • 7.1.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Impact of COVID-19 on new patients entering trials
  • Table 4 Impact of COVID-19 on other therapeutic areas

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Cell and gene therapy clinical trials market: Executive summary(2020)
  • Fig. 9 Cell and gene therapy clinical trials market: Strategy framework
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Companies with affected trials, by size
  • Fig. 14 Affected trials, by study phase
  • Fig. 15 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
  • Fig. 16 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
  • Fig. 17 Market driver relevance analysis (Current & future impact)
  • Fig. 18 Market restraint relevance analysis (Current & future impact)
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 21 Cell and gene therapy clinical trials market phase outlook: Segment dashboard
  • Fig. 22 Cell and gene therapy clinical trials market: Phase movement analysis
  • Fig. 23 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 24 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 25 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 26 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 27 Cell and gene therapy clinical trials market indication outlook: Segment dashboard
  • Fig. 28 Cell and Gene Therapy Clinical trials market: Indication movement analysis
  • Fig. 29 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 Cardiology market, 2018 - 2030 (USD Million)
  • Fig. 31 CNS market, 2018 - 2030 (USD Million)
  • Fig. 32 Musculoskeletal market, 2018 - 2030 (USD Million)
  • Fig. 33 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 34 Dermatology market, 2018 - 2030 (USD Million)
  • Fig. 35 Endocrine, metabolic, genetic market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunology & inflammation market, 2018 - 2030 (USD Million)
  • Fig. 37 Ophthalmology market, 2018 - 2030 (USD Million)
  • Fig. 38 Hematology market, 2018 - 2030 (USD Million)
  • Fig. 39 Gastrointestinal market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 Regional market: Key takeaways
  • Fig. 42 Regional market share, 2020
  • Fig. 43 Regional outlook, 2021 & 2030
  • Fig. 44 North America market, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 46 Canada market, 2018 - 2030 (USD Million)
  • Fig. 47 Europe market, 2018 - 2030 (USD Million)
  • Fig. 48 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 49 Germany market, 2018 - 2030 (USD Million)
  • Fig. 50 France market, 2018 - 2030 (USD Million)
  • Fig. 51 Italy market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 54 India market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan market, 2018 - 2030 (USD Million)
  • Fig. 56 China market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia market, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 61 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 63 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 64 MEA market, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 66 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 67 UAE market, 2018 - 2030 (USD Million)